image description

Tag: Bristol-Myers Squibb

LRA Brings Encouraging News from European Rheumatology Meeting

June 2, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results presented at the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress from a Phase 2 trial of its investigational biologic deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib […] Read More

Lupus Clinical Trials Redefined: You Make the Difference

Lupus Clinical Trials Redefined: You Make the Difference Lupus Clinical Trials Virtual Fair October 17, 2020 10:00 am to 1:00 pm ET Register Here Lupus clinical trials are still underway despite COVID-19. Making the process safer and easier for patients has never been more important. What is a clinical trial exactly? Why should I get involved […] Read More

Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus

New York, NY– June 27, 2019.  The Lupus Research Alliance (LRA) and its affiliate, Lupus Therapeutics, announced that it has broadened its collaboration with Bristol-Myers Squibb (BMS) to assess the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN). This expands the existing collaboration in systemic lupus erythematosus (SLE). Lupus nephritis refers […] Read More

Lupus Research Alliance and Lupus Therapeutics collaborate with Bristol-Myers Squibb on a New Lupus Trial

April 26, 2018 Lupus Research Alliance and Lupus Therapeutics collaborate with Bristol-Myers Squibb on a New Lupus Trial The Lupus Research Alliance today announced a collaboration between its newly formed affiliate, Lupus Therapeutics, and the pharmaceutical company, Bristol-Myers Squibb (BMS), to test a novel investigational drug, BMS-986165, as a potential new therapy for lupus. The […] Read More